OncLive TV

Hyman B. Muss, MD, sheds light on how the COVID-19 pandemic is impacting elderly patients with breast cancer and explains why geriatric patients are at a heightened risk of developing severe complications from the virus.

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).